AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05092854 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: Supplement will be created by the aminoVITAL company and will include all ingredients similar to the commercially available Rapid Recovery product except for the exclusion of the amino acid blend.
Study NCT05191251 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HEMSTOP questionnaire
Description: A HEMSTOP questionnaire is obtained during the anesthesia consultation.
Study NCT06266650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Treatment Technique- Muscle Energy Treatment
Description: Muscle Energy Treatment involves a patient actively using their muscles on request from a precisely controlled position, in a specific direction, against a distinctly executed counter force. During Muscle Energy Treatment, the physician positions the area of treatment into a position of resistance, which is the restrictive barrier. The physician then instructs the patient to use the targeted muscles for 3-5 seconds in the direction of ease while the physician provides a counterforce. The physician then tells the patient to stop contracting their muscles and evaluate the area for decreased tension, then repositions the patient into their new restrictive barrier. These steps are repeated three to five times and then the dysfunction is reevaluated.
Study NCT06266650 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Treatment Technique- Muscle Energy Treatment
Description: Muscle Energy Treatment involves a patient actively using their muscles on request from a precisely controlled position, in a specific direction, against a distinctly executed counter force. During Muscle Energy Treatment, the physician positions the area of treatment into a position of resistance, which is the restrictive barrier. The physician then instructs the patient to use the targeted muscles for 3-5 seconds in the direction of ease while the physician provides a counterforce. The physician then tells the patient to stop contracting their muscles and evaluate the area for decreased tension, then repositions the patient into their new restrictive barrier. These steps are repeated three to five times and then the dysfunction is reevaluated.
Study NCT05248035 — intervention group
Intervention type: OTHER
Intervention: Adult patient hospitalized in ICU
Description: acquisition of dynamic parameters in addition to pupillary diameter, such as . pupillary diameter, variation of the pupillary diameter, pupillary constriction speed, pupillary dilatation speed, photomotor reflex latency, NPi and symmetry of pupillary responses after a standardized light stimulus
Study NCT05553041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluciclovine PET-MRI
Description: 18F-Fluciclovine will be injected via IV prior to Positron emission tomography (PET)-Magnetic resonance imaging (MRI)
Study NCT06545786 — intervention group
Intervention type: DEVICE
Intervention: Intraoperative electroencephalography
Description: EEG recording will be performed using the standard 16-electrode configuration according to the international 10-20 system. During the recording, electrode impedances will be maintained at a level not exceeding 5 kilo-ohms.
Study NCT05764824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry powder
Description: 20 g per day of blueberry powder
Study NCT05764824 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Controlled and matched powder
Description: 20 g per day
Study NCT06020417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O-ARM (Medtronic, Inc, Louisville, CO)
Description: scanner that allows imaging of screws intraoperatively
Study NCT06020417 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional corrective surgery for arthrodesis
Description: Conventional procedure without neuronavigation guide
Study NCT06644014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participant will communicate with a chatbot-like proprietary AI to receive exercise instructions. The AI will provide personalized advice according to the user's needs, aiming for 2-3 hours of steady-state zone 2 -effort aerobic exercise. Instructions will also be tailored to the user's exercise preferences and limitations (for example, suggest cycling, if running is not convenient).
Study NCT06644014 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Supervised HIIT -cycling twice a week. Intensities for cycling intervals will are based on the participants fitness-level determined at first visit. Intensity will gradually increase over the 12-week period
Study NCT06644014 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Smart Ring
Description: Participants will only receive an Oura Ring, but will not change anything about their normal physical activity.
Study NCT05328505 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided Radiotherapy
Description: de-escalation radiotherapy to elective volumes + simultaneous integrated boost to PSMA avid lesions delivered in 20 fractions +/- ADT (clinical decision). The elective prostate bed and pelvic lymph node regions will receive 45 Gy. The PSMA-avid lymph node(s) will receive an SIB to 55-60 Gy and/or the PSMA-avid lesion in the prostate bed will receive an SIB to 60 Gy. Pelvic nodal treatment and ADT use will be left to the discretion of the treating physician.
Study NCT06632093 — intervention group
Intervention type: PROCEDURE
Intervention: hepatic artery infusion chemotherapy
Description: Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
Study NCT06632093 — intervention group
Intervention type: DRUG
Intervention: Lenvatinib + PD-1 monoclonal antibody
Description: PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
Study NCT06629402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF614
Description: Experimental oxycodone prodrug
Study NCT06629402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive medication
Study NCT06629597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL201
Description: YL201 will be administered intravenously on Day 1 of each 3-week cycle at RP3D dose level.
Study NCT06629597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered intravenously at 75 mg/m2 on Day 1 of each 3-week cycle.
Study NCT06629597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be administered orally at 1000 mg/m2 twice a day (BID) on Days 1 to 14 of each 3-week cycle
Study NCT06629597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously at 1000 mg/m2 on Day 1 and 8 of each 3-week cycle
Study NCT04515797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir and Pibrentasvir
Description: 4 weeks of treatment starting within 24 hrs of kidney transplant
Study NCT06511934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainGate Neural Interface System
Description: Placement of the BrainGate2 sensor(s) into arm-hand motor-related cortex.
Study NCT06377982 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hUCB
Description: hUCB
Study NCT06456554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix (Cortiva Tissue Matrix)
Description: non-crosslinked dermis
Study NCT06345443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside Malate
Description: Active supplement.
Study NCT06345443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06345443 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05417698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Only (Ex only)
Description: Unsupervised, home-based, equipment-free high-intensity interval training of 20 minutes exercise performed 3 times a week, for a duration of 8-weeks. Participants will perform exercises to their own suitability in a progressive manner throughout the 8-weeks. Exercises will be exerted at least ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals, as well as at least 17 out of 20 Rate of Perceived Exertion on the Borg Scale.
Study NCT05417698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and Mediterranean Diet (Ex + MedDiet)
Description: Participants in Ex+MedDiet arm adhere to a non-caloric restrictive Mediterranean diet throughout the 8-weeks comprising of a diet encompassing a focus on minimally processed food, incorporating a wide variety of fruits, vegetables, legumes and wholegrains, whilst utilising olive oil as the main source of fat. They will be encouraged to eat more oily and white fish, with moderate consumption of nuts, poultry and dairy products, and low consumption of red/processed meat and alcohol.~Participants will also perform unsupervised, home-based, equipment-free high-intensity interval training of 20 minutes exercise performed 3 times a week, for a duration of 8-weeks. Participants will perform exercises to their own suitability in a progressive manner throughout the 8-weeks. Exercises will be exerted at least ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals, as well as at least 17 out of 20 Rate of Perceived Exertion on the Borg Scale.
Study NCT05557721 — intervention group
Intervention type: PROCEDURE
Intervention: Topical lidocaine
Description: Patients will receive topical anesthesia with tetracaine hydrochloride 1% three times, 5 minutes apart. Then, lidocaine gel 2% will be applied on the surface of the eye and refilled as needed for 10 minutes, as well as manipulated for a good coverage.
Study NCT05557721 — intervention group
Intervention type: PROCEDURE
Intervention: MP-TLT
Description: Micro pulse transscleral laser treatment will be performed with the Iridex CycloG6 laser with the revised P3 probe, according to the recent consensus recommendations.~In brief, this includes MP-TLT with 2500 mW, 31.3% duty cycle, four 20 second sweeps per hemisphere, avoiding the 3 and 9 o'clock meridians and sectors with scleral thinning.
Study NCT06219213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glyceryl Eicosapentaenoate serum
Description: Daily application of serum on both targeted skin areas for 14 consecutive days. Serum must be applied before the Cream on clean skin.
Study NCT06219213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glyceryl Eicosapentaenoate Cream A
Description: Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
Study NCT06219213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glyceryl Eicosapentaenoate Cream B
Description: Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
Study NCT06219213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glyceryl Eicosapentaenoate Cream C
Description: Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
Study NCT05995782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB418
Description: Oral dose
Study NCT05995782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FB418
Description: Oral dose
Study NCT06095206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GenSci094
Description: On the morning of day 1 pre-meal, a single SC injection of 150 μg GenSci094 was administered in the abdominal wall.
Study NCT06122935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurora Xi New Nomogram Software 2.0
Description: Plasma collection with a proprietary plasma collection volume nomogram provides a more individualized approach to determining the volume of plasma collected from each donor.
Study NCT06122935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aurora Xi Currently Approved Software 1.3
Description: Plasma collection using the currently marketed Optimized Nomogram (software version 1.3) for the Aurora Xi Plasmapheresis System
Study NCT05896306 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05705401 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Adjuvant Breast Radiation
Description: adjuvant breast radiotherapy per the current standard of care
Study NCT05705401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
Description: participants are randomized to continue their standard of care systemic HER2-targeted therapy without adjuvant breast radiotherapy
Study NCT06185985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-812
Description: SPN-812 (200mg to 600mg once daily)
Study NCT05112315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predigraft
Description: The Subject randomized to the Predigraft will benefit from Predigraft, a remote monitoring software that issues an alert to the investigator when the allograft survival prediction calculated by the iBox algorithm is decreasing. This follow-up is on top of the site's standard of care.
Study NCT05763251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapy duration
Description: the standard-course arm will receive 14 days total of antifungal therapy and the short-course arm will only receive 7 days of therapy
Study NCT05718804 — intervention group
Intervention type: OTHER
Intervention: Whether renal injury occurred and differences in intestinal flora
Description: Whether renal injury occurred and differences in intestinal flora
Study NCT05228860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vida Sana (a Group Lifestyle Intervention)
Description: Vida Sana is a Group Lifestyle intervention that has been shown to be effective among patients with type 2 diabetes (T2DM). Vida Sana includes 23 group sessions with a trained health coach:~* Months 1-4: 1 family-wide orientation + 12 weekly sessions~* Months 5-6: 4 bimonthly group sessions~* Months 7-12: 6 monthly group sessions~All regular primary care and diabetes care will remain as usual.
Study NCT05228860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplemental Healthy Food Deliveries
Description: Participants will receive 12 weeks of weekly food deliveries from Dig Deep Farms.~Each delivery will include a selection of seasonal fresh vegetables and a rotation of either a whole grain or a whole-grain food (3+ grams of fiber/serving). Whole grains will include brown rice, oatmeal, barley, quinoa; whole grain foods will include cereal, pasta, tortillas, bread, crackers. Delivery sizes will be scaled to the three corresponding household sizes: 2-3 people; 4-5 people; or 6 or more people.~Food will be delivered by Dig Deep Farms, which already has an established food subscription delivery system.~(Control group participants will receive the same delivery schedule, but delayed to begin 6 months after their study enrollment.)
Study NCT05893121 — intervention group
Intervention type: OTHER
Intervention: Cardiac coherence session
Description: A cardiac coherence session consists of an exercise of six breaths per minute during five minutes.
Study NCT05893121 — intervention group
Intervention type: OTHER
Intervention: Information note about MRI
Description: explanatory note about MRI examination
Study NCT06533280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A, C and D: VH3739937 500 mg
Description: Oral administration of VH3739937 in moderate fat/moderate calorie conditions
Study NCT06533280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A, C and D: VH3739937 500 mg
Description: Oral administration of VH3739937 in moderate fat/moderate calorie conditions
Study NCT04589611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amobarbital/Gel-One (one dose)
Description: One dose of amobarbital/Gel-One during the initial surgical intervention
Study NCT04589611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amobarbital/Gel-One (one dose)
Description: One dose of amobarbital/Gel-One during the initial surgical intervention
Study NCT04589611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (single dose)
Description: One dose of placebo during the initial surgical intervention
Study NCT04589611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amobarbital/Gel-One (two doses)
Description: One dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
Study NCT04589611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (two doses)
Description: One dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
Study NCT05739123 — intervention group
Intervention type: DRUG
Intervention: Relugolix-Containing Product
Description: Any relugolix-containing therapy
Study NCT05964257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
Study NCT05964257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: Normal Saline will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
Study NCT04844866 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MB-CART2019.1
Description: MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.
Study NCT04378907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECIG Lab Session, 30 watts
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
Study NCT04378907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG Lab Session, 30 watts
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
Study NCT04844866 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: MB-CART2019.1
Description: MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.
Study NCT04844866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-GemOx or BR plus polatuzumab vedotin
Description: Immunochemotherapy will be administered as per arm description.
Study NCT05398120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Group
Description: Adolescents and young adults with a CHR syndrome ages 13-18 will complete feasibility and outcome measures while participating in a weekly skills group for 6 months.
Study NCT04899427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orelabrutinib
Description: Orelabrutinib will be given as 150mg per day orally, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
Study NCT04899427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
Study NCT04899427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
Study NCT06533280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: VH3739937 100 mg
Description: Oral administration of VH3739937 in moderate fat/moderate calorie conditions.
Study NCT06533280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A and C: Placebo
Description: Oral administration of Placebo in moderate fat/moderate calorie conditions
Study NCT06533280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Treatment A
Description: VH3739937, 500 mg(single dose given as 5 x 100 mg tablets). administered under moderate fat/moderate calorie conditions (reference)
Study NCT06533280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Treatment B
Description: VH3739937, 500 mg (single dose given as 500 mg tablet) administered under moderate fat/moderate calorie conditions (test)
Study NCT06533280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Treatment C
Description: VH3739937, 500 mg single tablet administered under fasted conditions.
Study NCT06533280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Treatment D
Description: VH3739937, 500 mg single tablet administered under low-fat/ low calorie conditions.
Study NCT06533280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Treatment E
Description: VH3739937, 500 mg single tablet administered under high-fat/ high calorie conditions.
Study NCT06533280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part D: Probe cocktail
Description: Oral administration of probe cocktail (Midazolam, Digoxin, Total Dabigatran etexilate, Rosuvastatin) in moderate fat/moderate calorie conditions.